NEFL and Alzheimer disease: In summary, although the results are promising, future longitudinal studies involving larger and more diverse cohorts should integrate serial biomarker measurements and include external validation analyses to determine whether plasma NfL can be considered a reliable tool to support clinical decision-making in AD management.